AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06298851 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neural Mobilization Group (NMG)
Description: Femoral nerve gliding: Mobilization of the femoral nerve will performed while the participant in the prone position and the hip hyperextended. Tension will applied by placing the knee in full flexion and the ankle in plantar flexion.~Sciatic nerve gliding: Participants will take turns while sitting with the trunk in thoracic flexion; perform knee extension/dorsiflexion with cervical extension and knee flexion/plantar flexion with cervical flexion. Tension will applied by flexing the hip and dorsiflexing the ankle to the point where stress will felt.~Peroneal nerve gliding: The participant will asked to maintain this position in a supine position by placing the ankle in inversion and plantar flexion. From a starting position consisting of ankle dorsiflexion, knee, and hip extension, the patient will return to the starting position by simultaneously performing ankle plantar flexion and inversion, full knee flexion, and 90 degrees of hip flexion.
Study NCT06298851 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic Stretching Group (DSG)
Description: Exercises will include functional activities that provided dynamic stretching of the hamstrings, quadriceps, hip flexor, extensor, abductor and adductor muscles, and gastrosoleus muscle. All stretching exercises will be performed in two circuits in an area of 15 m2. 4 sets of 10 repetitions will be performed, each exercise cycle lasting 6 seconds, and a 1-minute rest period will be given between sets. This process will be repeated for both extremities.
Study NCT06298851 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Static Stretching Group (SSG)
Description: Static stretching exercises will be described to the participants as given below:~Standing quadriceps stretch: The participant will stand upright, fold one knee and bring the heel towards the buttock while holding the foot with one hand.~Modified hamstring stretching: The participant will be in a seated position with one leg straight and will place the other foot on the inside of the straight leg and reach forward.~Gastrocnemius stretching: The participant stands with feet 60-90 cm from the wall, leaning against the wall with both hands, keeping the back leg straight and the front leg slightly bent.~Adductor stretching: Participants will be in a sitting position with an erect spine, bending and releasing their knees with the soles of their feet touching.~Lumbar stretching: In a sitting position, participants keep one leg straight and place the other foot on the outside of the straight leg and rotate the body diagonally.
Study NCT06084481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-400
Description: Intravenous (IV) Infusion
Study NCT06408337 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: implantation with an autologous human palatal mucosa substitute made of nanostructured fibrin-agarose generated by tissue engineering (BIOCLEFT).
Description: cleft palate repair surgery, all patients in the study will receive the standard treatment (uranostaphyllorrhaphy), with the only difference that patients assigned to the experimental study group will additionally have BIOCLEFT tissue obtained through tissue engineering grafted onto them. the lateral area of the palatine bone exposed when mobilizing the flaps. For the implant, the BIOCLEFT fabric will be placed in the area of exposed bone, sized to the size of the defect and sutured using uncoated, monofilament long-term absorbable synthetic suture.
Study NCT05750563 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: diosmin and micronized flavonoids
Description: the symptomatic treatment of haemorrhoids
Study NCT05750563 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Use as comparator
Study NCT05317429 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: A meal delivering 75 g of carbohydrate
Description: The nature of the test meal will depend upon the research question being addressed and it is anticipated that the test meals may include (but are not limited to) the following:~(i) Re-structured, enriched, and/or reformulated or non-conventionally processed food products (ii) Model food matrices with different structures or types of carbohydrate e.g. soups with different viscosity.
Study NCT05317429 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A meal delivering 75 g of carbohydrate
Description: The nature of the test meal will depend upon the research question being addressed and it is anticipated that the test meals may include (but are not limited to) the following:~(i) Re-structured, enriched, and/or reformulated or non-conventionally processed food products (ii) Model food matrices with different structures or types of carbohydrate e.g. soups with different viscosity.
Study NCT06039644 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Three-strain probiotic supplement includes Lactobacillus reuteri GMNL-89 (alive), Lactobacillus plantarum GMNL-141 (alive) and Lactobacillus paracasei GMNL-133 (alive).
Study NCT06039644 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Same additives to Probiotic group but replace probiotics with corn starch and Maltodextrin.
Study NCT06212986 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Promotion of mental training through mobile application Perform-UP Tennis
Description: Perform-UP Tennis is a sport specific mental training app that integrates breathing, relaxation and na-ture-based guided imagery exercises and aims to promote emotional well-being and the enhancement of mental skills. The app techniques are integrated into a single gradual path that involves increasingly complex breathing and relaxation exercises with increasing duration.~The intervention consists of eight weekly modules over a period of 8 weeks with progressive exercises.
Study NCT05603585 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Optimal protein supplementation to achieve 80% protein adequacy.
Description: Additional protein required and delivered by adding protein powder and given in bolus feeds
Study NCT05482503 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 12-Lead ECG(I-lead)
Description: All participants will simultaneously record 12-lead ECGs(I-lead)
Study NCT04743934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flibanserin 100 MG
Description: Flibanserin 100mg tablets taken by mouth daily at bedtime
Study NCT04743934 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Visually identical placebo tablets taken by mouth daily at bedine
Study NCT04743934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy
Description: Androgen deprivation therapy consisting of a GnRH agonist or antagonist, choice of agent at discretion of treating physician.
Study NCT04743934 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Androgen deprivation therapy
Description: Androgen deprivation therapy consisting of a GnRH agonist or antagonist, choice of agent at discretion of treating physician.
Study NCT05220514 — intervention group
Intervention type: DRUG
Intervention: (R)-1-(2-chlorophenyl)- N-[11C] ([11C] PK11195)
Description: Radiotracer used during the PET-MR scan of the study to identify signs of disease. Used in studies related to Alzheimer's disease. Only FDA approved for investigational use.
Study NCT05423522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NanoLithium® NP03
Description: One administration of 3 mL per day (1.8 mg/day) by depositing 1.5 mL in the gingivo-jugal groove of each cheek with the graduated pipette.
Study NCT05423522 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One administration of 3 mL per day (1.8 mg/day) by depositing 1.5 mL in the gingivo-jugal groove of each cheek with the graduated pipette.
Study NCT05534321 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Prophylactic Radiotherapy
Description: Radiation therapy will be delivered according to department standards. For this protocol, total dose and dose fractionation may be delivered at the discretion of the treating radiation oncologist according to department standards. All techniques including conventional, three-dimensional conformal radiation therapy (3D-CRT), intensity-modulated radiation therapy (IMRT), and stereotactic radiosurgery/stereotactic body radiation therapy (SRS/SBRT) techniques may be used. Image guidance at the time of treatment delivery to verify patient positioning may be chosen at the discretion of the treating radiation oncologist according to department standards.
Study NCT05534321 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care systemic therapy
Description: Standard of care systemic therapy, including chemotherapeutics, targeted therapies, immunomodulatory agents, and hormonal therapies will be delivered at the discretion of the treating medical oncologist. Patients may receive systemic therapy concurrently and there are no restrictions on initiation of systemic agents after radiotherapy including immunotherapy and hormonal therapy, the timing of which will be determined by a consensus between the treating medical and radiation oncologists.
Study NCT06630494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human thrombopoietin for injection (rhTPO)
Description: Single abdominal subcutaneous injection of the study drug will be given on D1. The administration and follow-up observation period will be 29 days (D1\~D29). Participants may be discharged at D7 at the judgment of the investigator. PK blood samples will be collected from D-1 to D14, tolerance and safety will be observed from D1 to D29, and blood samples for PD and anti-drug antibody (ADA) will be collected from screening to D29. After completion of relevant assessments on D29, participants will be considered as having completed this study.
Study NCT06246084 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Endocrine Therapy Education Program
Description: Brief, video-based intervention program to improve endocrine therapy adherence and experiences and to provide detailed education to participants. The intervention is distributed and assessed via the MyEmma platform, a HIPAA-compliant, online communications platform.
Study NCT06502366 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BDA MDI HFO 160/180 μg
Description: Budesonide/albuterol pressurized inhalation suspension, HFO
Study NCT06502366 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BDA MDI HFA 160/180 μg
Description: Budesonide/albuterol pressurized inhalation suspension, HFA
Study NCT06502366 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo MDI HFA
Description: Placebo pressurized inhalation suspension, HFA
Study NCT05220514 — intervention group
Intervention type: DRUG
Intervention: 2-(4-[11C]methylamino phenyl)-6-hydroxybenzothiazole (11C]6-OH-BTA-1 or [11C]PIB)
Description: Radiotracer used during the PET-MR scan of the study to identify signs of disease. Used in studies related to Alzheimer's disease. Only FDA approved for investigational use.
Study NCT06202703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pneumococcal Vaccine
Description: vaccination with pneumococcal vaccine (PCV13)
Study NCT04727736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-DCFPyL
Description: 18F-DCFPyL (single dose injection) - a radiolabeled prostate-specific membrane antigen (PSMA) ligand
Study NCT04464967 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SNK01
Description: Patient-specific ex vivo expanded autologous natural killer cells
Study NCT04464967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: HER2 receptor antagonistic, humanized immunoglobulin G subclass 1 (IgG1) monoclonal antibody
Study NCT04464967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: EGFR antagonist, chimeric immunoglobulin G subclass 1 (IgG1) monoclonal antibody
Study NCT06170944 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning
Description: The patients in experiment group will receive treatment with RIC (5 cycles of cuff inflation for 5 minutes and deflation for 5 minutes to the bilateral upper limbs to 200 mmHg) for 1 year as an adjunct to guideline-based treatment.
Study NCT06383026 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Breast Cancer Screening
Description: Screening mammography as well as whole breast ultrasound interpreted by BI-RADS.
Study NCT06383026 — intervention group
Intervention type: OTHER
Intervention: Survey/Interview
Description: A mixed-methods approach including electronic surveys and one on one interviews.
Study NCT06383026 — intervention group
Intervention type: OTHER
Intervention: Focus Group
Description: A semi-structured focus group with open-ended questions that explores faculty and staff experiences in a breast cancer screening program for transgendered and nonbinary persons.
Study NCT06008210 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision Support Intervention
Description: The participants will receive two 60-minute consultation sessions delivered by a trained nurse in four weeks at home. Participant's family members will be encouraged to attend the sessions. In the first session, the nurse will explore the participant's understanding of the current health condition, introduce the concept of advance care planning and discuss their decisional needs for end-of-life care decision-making. In the second session, the nurse will ask the participants to complete a value clarification exercise individually.
Study NCT06008210 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Coaching
Description: The participants will receive two 60-minute health coaching sessions delivered by a trained nurse in four weeks at home. This intervention will focus on lifestyle modification and self-care management unrelated to the tested intervention content or outcomes.
Study NCT06424561 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological Intervention Group
Description: The intervention group provides psychological education to patients, emphasizing participation in a Surgery Success patient group organized by researchers, and collects successful patient cases for promotion. Patients are encouraged to learn from successful cases within the group. Psychological intervention is also provided to family members, as they are the primary caregivers, and guiding their thoughts is crucial. Timely identification of patients with psychological abnormalities is conducted, with psychological consultations if necessary. Targeted measures are taken for patients with psychological abnormalities. Upon discharge, one-on-one consultation and tracking services are provided by designated nurses to alleviate patients' feelings of helplessness and despair, continuing until the patient fully recovers.
Study NCT04875910 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based exercise program
Description: The exercise program will include task specific training to improve balance and the training will progress every two weeks. A Physical therapist will be following up and monitoring the participants adherence to the training by audio or video call.~The exercise program for Week 1: Sit to Stand 5 times, Steps forward, backward and to the sides 5 times, 10 meters walk. 45 minutes session /3 times per week. Week 2: Sit to stand 10 times, Steps forward, backward and to the sides 5 times , Sit and reach 5 min for each hand and walk for 15 meters. 45 minutes session, 3 times per week. Week3 Sit to stand 10 times, Step on bench 5 times, Stand and reach 5 and walk for 15 meters. 45 minutes session, 3 times per week. Week 4 Stand and reach 5 times, Step on bench 10 times, climbing stairs (5 steps flight stairs up and down) and walk for 20 meters. 50 minutes session, 3 times per week.
Study NCT05710900 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: Each dietary remission strategy involves three phases focused on weight loss and medication deprescribing (Phase 1: Weeks 0-12), transition to an individualized sustainable dietary pattern (Phase 2: Weeks 13-20), and weight loss/remission maintenance (Phase 3: Weeks 21-52).
Study NCT05681013 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Laughter Therapy
Description: The effect of the Laughter Therapy on nursing students
Study NCT05183334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg
Description: PD5I
Study NCT05183334 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT05183334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol Hydrochloride 100 MG
Description: opiod
Study NCT05704855 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined Exercise + Behavioural Counselling
Description: The combine exercise intervention will consist of three 30-minute, supervised, remotely-delivered resistance training classes as well as three 30-minute, unsupervised aerobic training (i.e., walking) sessions each week. Participants will also participate in bi-weekly, 45-60 minute, remotely-delivered, group-based behavioural counselling sessions delivered via videoconferencing (i.e., Zoom). Participants will be asked to participate in the intervention for 8 weeks.
Study NCT05704855 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: The active control group will participate in three 30-minute, supervised, remotely-delivered classes targeting balance and flexibility. The program will be delivered at a low-intensity by a Registered Kinesiologist via videoconferencing (i.e., Zoom). Participants will be asked to participate in the program for 8 weeks.
Study NCT06431945 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Hepatitis C antibody (anti-HCV) test
Description: Testing for hepatitis C antibodies determines whether or not you have been exposed to HCV at some point in your life. This testing will be performed in all 3,000 persons who inject drugs enrolled in the project.
Study NCT06431945 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Hepatitis C RNA test and genotype test
Description: RNA is a type of genetic material from HCV that can be detected in the blood. This test will be used as a confirmation of the infection. This testing will be performed in all persons with positive antibody test who will come to clinical center.
Study NCT05411835 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional Ketone Supplement
Description: Mix of sodium, calcium, and magnesium salts of D-beta-hydroxybutyrate with nicotinamide riboside chloride, flavors and stevia sweetener
Study NCT05411835 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Isocaloric Placebo Supplement
Description: Maltodextrin with flavors and stevia sweetener
Study NCT06285890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HC-7366
Description: Given by PO
Study NCT04991857 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: T-FAME-HF
Description: 16-week program adopts a hybrid approach to combine nurse-led home visits, an Apps, tele-care and optimized family support to enhance post-discharge disease management, disease monitoring, and patients' access to the nurse, and telephone visits
Study NCT04991857 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group - HF education program
Description: For patients assigned to the control arm will receive HF education program, the care dyad will receive a 16-week HF education program that comprises a home visit by the team nurse, five bi-weekly online training on self-care through videos on Whatapps/ WeChat with two subsequent telephone follow-up.
Study NCT06235983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3537982
Description: Administered orally.
Study NCT05664737 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Luspatercept
Description: Specified dose on specified days
Study NCT05664737 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days
Study NCT05906628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib cream
Description: Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
Study NCT05906628 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle cream is a topical formulation applied as a thin film to affected areas.
Study NCT05200377 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic resonance imaging
Description: Patients recruited will receive Magnetic resonance imaging.
Study NCT05105672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: IV infusion
Study NCT05105672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV infusion
Study NCT05105672 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiotherapy (EBRT)
Description: Undergo pelvic EBRT
Study NCT05105672 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: brachytherapy
Description: brachytherapy
Study NCT06090968 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Umbilical cord milking
Description: 20 cm of umbilical cord would be milked towards the infant with intact umbilical cord. The cord milking will be done four times. The entire procedure can be done in 15-20 seconds
Study NCT06090968 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate cord clamping
Description: clamping the umbilical cord as soon as possible (average 30 seconds)
Study NCT05403086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Psilocybin, \[3-\[2-(dimethylamino)ethyl\]-1H-indol-4-yl\] dihydrogen phosphate.